Amarin has announced that the European Phase III clinical trial of Miraxion in Huntington's disease has commenced. A similar U.S. Phase III clinical trial began dosing in September.
The U.S. and European trials are multicenter, randomized, double blind, placebo-controlled studies of Miraxion at 43 sites in the U.S. and up to 33 sites in Europe. The trials are planned to enroll 540 Huntington's disease patients, with approximately 300 in the U.S. trial and approximately 240 in the European trial over a six-month period. Patients in the U.S. trial will participate in a further six-month extension period.